NEOS Investment Management LLC Has $1.64 Million Holdings in Exelixis, Inc. (NASDAQ:EXEL)

NEOS Investment Management LLC increased its position in Exelixis, Inc. (NASDAQ:EXEL) by 21.4% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 49,256 shares of the biotechnology company’s stock after purchasing an additional 8,674 shares during the period. NEOS Investment Management LLC’s holdings in Exelixis were worth $1,640,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. MassMutual Private Wealth & Trust FSB lifted its holdings in shares of Exelixis by 18.1% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,890 shares of the biotechnology company’s stock valued at $63,000 after purchasing an additional 290 shares in the last quarter. Steward Partners Investment Advisory LLC lifted its stake in Exelixis by 4.9% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 7,050 shares of the biotechnology company’s stock worth $235,000 after acquiring an additional 330 shares in the last quarter. Oregon Public Employees Retirement Fund boosted its position in Exelixis by 0.6% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 58,159 shares of the biotechnology company’s stock worth $1,937,000 after acquiring an additional 354 shares during the period. Principal Securities Inc. grew its stake in Exelixis by 62.8% during the 4th quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 373 shares in the last quarter. Finally, V Square Quantitative Management LLC increased its holdings in shares of Exelixis by 37.3% in the 4th quarter. V Square Quantitative Management LLC now owns 1,563 shares of the biotechnology company’s stock valued at $52,000 after purchasing an additional 425 shares during the period. Institutional investors and hedge funds own 85.27% of the company’s stock.

Exelixis Trading Down 0.4 %

NASDAQ EXEL opened at $36.70 on Friday. Exelixis, Inc. has a 1 year low of $20.14 and a 1 year high of $40.02. The company has a fifty day simple moving average of $35.71 and a 200 day simple moving average of $33.27. The company has a market cap of $10.27 billion, a P/E ratio of 20.73, a P/E/G ratio of 1.13 and a beta of 0.57.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. Equities research analysts forecast that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

Insider Buying and Selling at Exelixis

In other Exelixis news, Director Jack L. Wyszomierski sold 8,768 shares of the stock in a transaction on Friday, February 28th. The shares were sold at an average price of $37.80, for a total value of $331,430.40. Following the completion of the sale, the director now directly owns 356,605 shares of the company’s stock, valued at $13,479,669. This represents a 2.40 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Patrick J. Haley sold 10,000 shares of the firm’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $38.80, for a total transaction of $388,000.00. Following the completion of the sale, the executive vice president now owns 341,028 shares in the company, valued at $13,231,886.40. This represents a 2.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 140,343 shares of company stock valued at $5,177,234 in the last 90 days. 2.85% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

EXEL has been the topic of a number of research analyst reports. Wells Fargo & Company downgraded shares of Exelixis from an “overweight” rating to an “equal weight” rating and set a $36.00 price objective on the stock. in a research report on Monday, February 24th. JMP Securities reissued a “market outperform” rating and set a $41.00 target price on shares of Exelixis in a research note on Thursday, January 23rd. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price target on shares of Exelixis in a research note on Thursday. Guggenheim reissued a “buy” rating and set a $42.00 price objective on shares of Exelixis in a research report on Wednesday, February 12th. Finally, BMO Capital Markets downgraded Exelixis from an “outperform” rating to a “market perform” rating and boosted their target price for the company from $36.00 to $40.00 in a research note on Friday, December 20th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Exelixis presently has an average rating of “Moderate Buy” and a consensus target price of $37.59.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.